BAP1 Loss Might Be a Predictive Biomarker for Immunotherapy Response in Pleural Mesothelioma
Thoracic Cancer · 2026-07 · 17 (13)
DOI: 10.1111/1759-7714.70343 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 01.07.2026. Verfasst von Reina Imase und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Institute of Science Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Ubiquitin Thiolesterase, Tumor Suppressor Proteins, Biomarkers, Tumor, Pleural Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan, including JSPS KAKENHI.
Abstract (Originalsprache)
Introduction
Reliable predictive biomarkers for immune checkpoint inhibitors (ICIs) in pleural mesothelioma (PM) are lacking. Loss of BRCA1‐associated protein 1 (BAP1) is a frequent molecular alteration in PM and may influence the tumor immune microenvironment. We evaluated whether BAP1 loss is associated with clinical outcomes following immunotherapy.
Methods
We retrospectively analyzed 14 patients with PM who were treated with ICIs between April 2014 and May 2024. BAP1 status was assessed by immunohistochemical staining of resected tumor specimens. Patients were categorized into BAP1‐loss and BAP1‐positive groups. Progression‐free survival (PFS), overall survival (OS), response rate (RR), and disease control rate (DCR) were compared.
Results
BAP1 loss was observed in nine patients (64%). Median PFS was significantly longer in the BAP1‐loss group compared with the BAP1‐positive group (5.3 vs. 2.1 months; log‐rank p = 0.03). Median OS was also prolonged in the BAP1‐loss group (8.6 vs. 2.1 months; log‐rank p = 0.03). RR and DCR were numerically higher among patients with BAP1 loss.
Conclusion
BAP1 loss was associated with improved clinical outcomes following immunotherapy in PM. These findings support that a molecular profile that includes BAP1 deletion may serve as a biomarker for predicting response to immunotherapy in PM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Institute of Science Tokyo, Tokyo, Japan.
- Department of Pathology, Institute of Science Tokyo, Tokyo, Japan.
- Department of Thoracic Surgery, Institute of Science Tokyo, Tokyo, Japan.
ORCID-Profile: Reina Imase, Rie Sakakibara, Yasunari Miyazaki
Förderung
- Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan, including JSPS KAKENHI
Zitieren
APA
Imase, R., Sakakibara, R., Kirimura, S., Ishibashi, H., Okubo, K., & Miyazaki, Y. (2026). BAP1 Loss Might Be a Predictive Biomarker for Immunotherapy Response in Pleural Mesothelioma. Thoracic Cancer, 17(13). https://doi.org/10.1111/1759-7714.70343
Vancouver
Imase R, Sakakibara R, Kirimura S, Ishibashi H, Okubo K, Miyazaki Y. BAP1 Loss Might Be a Predictive Biomarker for Immunotherapy Response in Pleural Mesothelioma. Thoracic Cancer. 2026;17(13). doi:10.1111/1759-7714.70343
BibTeX
@article{Imase2026,
author = {Imase, Reina and Sakakibara, Rie and Kirimura, Susumu and Ishibashi, Hironori and Okubo, Kenichi and Miyazaki, Yasunari},
title = {BAP1 Loss Might Be a Predictive Biomarker for Immunotherapy Response in Pleural Mesothelioma},
journal = {Thoracic Cancer},
year = {2026},
volume = {17},
number = {13},
doi = {10.1111/1759-7714.70343}
}
EUVIMED